Most Popular
1. It’s a New Macro, the Gold Market Knows It, But Dead Men Walking Do Not (yet)- Gary_Tanashian
2.Stock Market Presidential Election Cycle Seasonal Trend Analysis - Nadeem_Walayat
3. Bitcoin S&P Pattern - Nadeem_Walayat
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
4.U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - Raymond_Matison
5. How to Profit from the Global Warming ClImate Change Mega Death Trend - Part1 - Nadeem_Walayat
7.Bitcoin Gravy Train Trend Forecast 2024 - - Nadeem_Walayat
8.The Bond Trade and Interest Rates - Nadeem_Walayat
9.It’s Easy to Scream Stocks Bubble! - Stephen_McBride
10.Fed’s Next Intertest Rate Move might not align with popular consensus - Richard_Mills
Last 7 days
Friday Stock Market CRASH Following Israel Attack on Iranian Nuclear Facilities - 19th Apr 24
All Measures to Combat Global Warming Are Smoke and Mirrors! - 18th Apr 24
Cisco Then vs. Nvidia Now - 18th Apr 24
Is the Biden Administration Trying To Destroy the Dollar? - 18th Apr 24
S&P Stock Market Trend Forecast to Dec 2024 - 16th Apr 24
No Deposit Bonuses: Boost Your Finances - 16th Apr 24
Global Warming ClImate Change Mega Death Trend - 8th Apr 24
Gold Is Rallying Again, But Silver Could Get REALLY Interesting - 8th Apr 24
Media Elite Belittle Inflation Struggles of Ordinary Americans - 8th Apr 24
Profit from the Roaring AI 2020's Tech Stocks Economic Boom - 8th Apr 24
Stock Market Election Year Five Nights at Freddy's - 7th Apr 24
It’s a New Macro, the Gold Market Knows It, But Dead Men Walking Do Not (yet)- 7th Apr 24
AI Revolution and NVDA: Why Tough Going May Be Ahead - 7th Apr 24
Hidden cost of US homeownership just saw its biggest spike in 5 years - 7th Apr 24
What Happens To Gold Price If The Fed Doesn’t Cut Rates? - 7th Apr 24
The Fed is becoming increasingly divided on interest rates - 7th Apr 24
The Evils of Paper Money Have no End - 7th Apr 24
Stock Market Presidential Election Cycle Seasonal Trend Analysis - 3rd Apr 24
Stock Market Presidential Election Cycle Seasonal Trend - 2nd Apr 24
Dow Stock Market Annual Percent Change Analysis 2024 - 2nd Apr 24
Bitcoin S&P Pattern - 31st Mar 24
S&P Stock Market Correlating Seasonal Swings - 31st Mar 24
S&P SEASONAL ANALYSIS - 31st Mar 24
Here's a Dirty Little Secret: Federal Reserve Monetary Policy Is Still Loose - 31st Mar 24
Tandem Chairman Paul Pester on Fintech, AI, and the Future of Banking in the UK - 31st Mar 24
Stock Market Volatility (VIX) - 25th Mar 24
Stock Market Investor Sentiment - 25th Mar 24
The Federal Reserve Didn't Do Anything But It Had Plenty to Say - 25th Mar 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

British Billionaire Jim Mellon Says Biotech Is the Best Investment Now

Companies / BioTech Apr 05, 2017 - 03:27 PM GMT

By: John_Mauldin

Companies

BY PATRICK COX : We are in the midst of an unprecedented change. Life spans have nearly doubled since the beginning of the 20th century. In addition, recent advances in computer technology have had a huge impact on biological sciences, which means this trend will accelerate.

Still, most people think that the process of aging will go on pretty much as it is now. They’re wrong.


Discoveries have been made that will yield radical increases in healthy life expectancies. These biotechnologies will change everything— the way we live... and the way we invest. I write about the most promising of these breakthroughs in Tech Digest (subscribe here for free).

Longer, Healthier Life Spans Require Dramatic Change

Social security programs were implemented when almost no one lived past the age of 65.

Today, these programs won’t survive without radical restructuring. Pension programs designed using old actuarial tables will collapse. Healthcare, our largest financial sector, will barely resemble the current model.

Diseases we fear today will soon become minor issues, and companies that provide traditional treatments will be bankrupted. Why? Artificial intelligence and personalized genome analysis will be the norm.

The public is just starting catch on. Government policymakers and portfolio managers will have to adapt to this new reality. Then, the biotech sector will escape the ghetto status it too often suffers from.

That’s why I’m always on the lookout for signs that opinion leaders are waking up to the coming biotech revolution.

One of the most promising signs was when Silicon Valley’s wealthiest entrepreneurs embraced anti-aging research a few years back. (You might recall headlines like “6 Billionaires Who Want To Live Forever.”)

My impression, though, is that most people view Peter Thiel, Larry Ellison, and Larry Page as wealthy eccentrics. With so much money in their bank accounts, people think these men can afford to squander it on costly and unrealistic pet projects.

In fact, I haven’t been impressed by the way they’ve spent their money either. Instead of funding well-validated anti-aging compounds that could be ready in just a few years, they’ve started from scratch.

Some of the research funded by tech billionaires is interesting, but it won’t reach the market for a decade or two. That’s just too long for most people to take seriously.

Plus, we don’t have that much time to rescue Social Security and Medicare. If we don’t cut the cost of age-related disease and prolong healthy working careers soon, the entire system will collapse.

A New Voice Champions the Biotech Solution

British economist Jim Mellon is now beating the biotech drum. European readers are already well-acquainted with him. Mellon has made a billion dollars based on a long series of remarkably accurate financial predictions.

Though his name may not be as well known in the US, sophisticated financial analysts are aware of his track record. In fact, my boss, John Mauldin, is interested in many of the same issues and wrote an endorsement for Mellon’s latest book.

Mellon sees the big macroeconomic picture. Unlike the tech billionaires, he knows what demographic aging and plummeting birthrates are doing to government budgets in Europe and North America.

He also knows that anti-aging biotechnologies are the only way to fix those problems… which means these breakthroughs will eventually be embraced.

Europe’s aging problem is worse than the US’s, so it needs biotech solutions soon. Mellon’s views are getting traction on the continent, and that is very good news for us. It can only help spread the message across to our side of the Atlantic.

Stay in the Loop on Life-Extending Research with Patrick Cox's Tech Digest

This weekly newsletter by biotech expert Patrick Cox highlights research that is much more advanced than most people know, and the profit potential for investors is vast. Read about the latest breakthroughs—from new, non-invasive cancer treatments to age-reversing nutraceuticals and vaccines that kill any virus–as well as the innovative companies that work on them. Get Tech Digest free in your inbox every Monday.

John Mauldin Archive

© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in